Clinical Trials Directory

Trials / Unknown

UnknownNCT04451616

Assessment of Progranulin and FAM19A5 Protein Blood Levels in Metabolic Syndrome

Assessment of Progranulin and Chemokine-like Protein TAFA-5 (FAM19A5) Blood Levels in Adults With Metabolic Syndrome

Status
Unknown
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
Poznan University of Medical Sciences · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Accepted

Summary

The main objective of the study is to assess the serum levels of progranulin and FAM19A5 protein in adults with metabolic syndrome.

Detailed description

The study is planned to be conducted on 40 adults with metabolic syndrome. As a control, it is planned to recruit 40 adults without metabolic syndrome. From all participants fasting venous blood samples, urine samples and hair samples will be collected. Next, serum progranulin and serum FAM19A5 protein concentrations will be determined in both groups. Also, serum concentration of leptin, vascular endothelial growth factor (VEGF), insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Serum, hair and urine mineral content will be determined. In whole blood genetic analyses will be performed in order to detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and genes associated with the body's mineral metabolism. Also, body composition analysis, blood pressure measurement, pulse measurement, blood oxygen saturation measurement and nutritional interview will be performed.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTBlood sample collectionFasting blood sample will be collected from forearm vein. In the sample the concentration of: progranulin and serum FAM19A5 protein, leptin, VEGF, insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Whole blood sample will be secured to isolate genetic material, detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and with the body's mineral management. Serum mineral analysis will be performed.
DIAGNOSTIC_TESTHair sample collectionHair sample collection will be performed. Hair mineral analysis will be performed.
DIAGNOSTIC_TESTUrine sample collectionUrine sample collection will be performed. Urine mineral analysis will be performed.
DIAGNOSTIC_TESTBody composition analysisBody composition analysis with the use of electric bioimpedance will be performed.
DIAGNOSTIC_TESTQuestionnairesDietary and lifestyle interview with the use of dietary and lifestyle questionnaires and dietary diaries will be performed.
DIAGNOSTIC_TESTBlood pressure, pulse and blood oxygen saturation measurementBlood pressure, pulse and blood oxygen saturation measurements with the use of non-invasive methods will be performed.

Timeline

Start date
2020-07-03
Primary completion
2021-06-01
Completion
2021-06-01
First posted
2020-06-30
Last updated
2020-08-14

Locations

1 site across 1 country: Poland

Source: ClinicalTrials.gov record NCT04451616. Inclusion in this directory is not an endorsement.